Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial

IF 25.3 1区医学 Q1 UROLOGY & NEPHROLOGY

European urology Pub Date : 2025-02-01 DOI:10.1016/j.eururo.2024.03.023

Sumanta K. Pal , Petros Grivas , Shilpa Gupta , Nazli Dizman , Zeynep Zengin , Begona P. Valderrama , Alejo Rodriguez-Vida , Florian Roghmann , Elena Sevillano Fernandez , Surena F. Matin , Yohann Loriot , Srikala S. Sridhar , Guru Sonpavde , Mark T. Fleming , Seth P. Lerner , Joaquim Bellmunt , Viraj Master , Abhishek Tripathi , Kim Davis , David van Veenhuyzen , Siamak Daneshmand

引用次数: 0

查看原文本刊更多论文

英夫拉替尼与安慰剂相比，可用于治疗带有 FGFR3 基因组变异的高风险已切除尿路上皮癌患者：PROOF302 3 期试验结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology 医学-泌尿学与肾脏学

CiteScore

43.00

自引率

2.60%

发文量

1753

审稿时长

23 days

期刊介绍： European Urology is a peer-reviewed journal that publishes original articles and reviews on a broad spectrum of urological issues. Covering topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, the journal also highlights recent advances in techniques, instrumentation, surgery, and pediatric urology. This comprehensive approach provides readers with an in-depth guide to international developments in urology.